Andy Kidd, Aptinyx CEO
After imploding three years ago, Aptinyx follows a painful setback with yet another PhII failure
More than three years after Aptinyx shares $APTX were squashed by a mid-stage setback for its lead drug, the biotech has unveiled the bottom-line results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
